الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 110 |  |  |
| | | from | 110 | | |
Abstract
The pharmaceutical research was directed to natural products’ discovery especially from actinomycetes as one of the major source of bioactive compounds due to unwanted adverse reactions and antimicrobial resistance with some current agents. Metabolomics- and dereplication-guided approach has been used successfully in chemical profiling of bioactive actinomycetes. We aimed to study the metabolomic profile of five bioactive actinomycetes to investigate the interesting metabolites responsible for their antimicrobial and anticancer activities. Three actinomycetes, namely, SH8, SH10, and SH13, were found to exhibit broad spectrum of antimicrobial activities, whereas isolate SH4 showed the broadest antimicrobial activity against all tested strains. In addition, isolates SH8, SH10, and SH12 displayed potent cytotoxicity against the breast cancer cell line MCF-7, whereas isolates SH4 and SH12 exhibited potent anticancer activity against the hepatoma cell line HepG2 compared with their weak inhibitory properties on the normal breast cells MCF-10A and normal liver cells THLE2, respectively. All bioactive isolates were molecularly identified as Streptomyces sp. via 16S rRNA gene sequencing. Our actinobacterial dereplication analysis revealed putative identification of several bioactive metabolites including tetracycline, oxytetracycline and a macrolide antibiotic, novamethymycin. Together, chemical profiling of bioactive Streptomycetes via dereplication and metabolomics helped in assigning their unique metabolites and predicting the bioactive compounds instigating their diverse bioactivities.